All In Biotech

Drug Trial Radar · NCT03940703

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

140

Actual

Start

Sep 19, 2019

Primary completion

May 11, 2023

Study completion Jul 15, 2026

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
May 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • TepotinibDrug

    Participants were administered with Tepotinib orally once daily at a dose of 500 mg.

  • OsimertinibDrug

    Participants received Osimertinib at a dose of 80 mg orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combined Therapy (Tepotinib+Osimertinib): Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version (NCI-CTCAE v 5.0)Time frame: Up to Day 21 of Cycle 1 (each Cycle is of 21 days)
  2. Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Fluorescence in Situ Hybridization(FISH)Time frame: Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)

Locations

179 sites in 17 countries. Site status is shown where the registry gives one.

  • Yuma Regional Medical Center

    Yuma, Arizona

  • Compassionate Care Research Group Inc - Edinger Medical Group, Inc.

    Fountain Valley, California

  • Memorial Care

    Long Beach, California

  • Ventura County Hematology Oncology Specialists

    Oxnard, California

  • Innovative Clinical Research Institute

    Whittier, California

  • Eastern Connecticut Hematology & Oncology Associates

    Norwich, Connecticut

  • Holy Cross

    Fort Lauderdale, Florida

  • Memorial Healthcare System

    Hollywood, Florida

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Ocala Oncology

    Ocala, Florida

  • University Cancer and Blood Center

    Athens, Georgia

  • Hawaii Cancer Care

    Honolulu, Hawaii

  • University of Chicago Medical Center

    Chicago, Illinois

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana

  • Community Health Network

    Indianapolis, Indiana

  • Beacon Health

    South Bend, Indiana

  • Norton Cancer Institute

    Louisville, Kentucky

  • Pontchartrain

    Hammond, Louisiana

  • Medstar Franklin Square Clinical Research Center

    Baltimore, Maryland

  • The Center for Cancer & Blood Disorders - Maryland

    Bethesda, Maryland

  • Frederick Health- James M Stockman Cancer Institute

    Frederick, Maryland

  • Boston Medical Center - Dept. Hematology/Oncology

    Boston, Massachusetts

  • Southcoast Center for Cancer Care

    Fairhaven, Massachusetts

  • Sparrow Hospital Herbert - Herman Cancer Center

    Lansing, Michigan

  • Central Care Cancer Center (CCCC)

    Bolivar, Missouri

  • St. Louis Cancer Care, LLP

    Bridgeton, Missouri

  • Mosaic Life Care

    Saint Joseph, Missouri

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • New Jersey Cancer Care and Blood Disorders

    Belleville, New Jersey

  • Summit Medical Group

    Florham Park, New Jersey

  • NYU Langone Clinical Cancer Center - NYU Langone Medical Center

    New York, New York

  • NYU Langone Clinical Cancer Center - NYU Langone Medical Cente

    New York, New York

  • Weill Cornell Medical College - Gastroenterology

    New York, New York

  • Southeastern Medical Oncology Center

    Goldsboro, North Carolina

  • University Hospitals Seidman

    Cleveland, Ohio

  • OhioHealth

    Columbus, Ohio

  • Oklahoma Cancer Specialists and Research Institute

    Tulsa, Oklahoma

  • Oregon Oncology Specialists

    Salem, Oregon

  • Gettysburg Cancer Center

    Gettysburg, Pennsylvania

  • Sanford Health

    Sioux Falls, South Dakota

Showing 40 of 179 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.